Skip to main content
Skip to section navigation
Skip to footer
About Us
Company Overview
Management
Board of Directors
Pipeline
Pipeline Overview
Paxalisib
PD-L1 Protein Degrader
SETDB1 Inhibitor
EVT801
Clinical Trials
Posters & Publications
Technology
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Investors
Investors Overview
News & Events
Company Info
Financial Results
Stock Data
SEC Filings
Governance
ASX Delisting
Contact Us
ASX Announcements
Media Center
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Oct 24, 2023
Kazia announces Clinical Data at ESMO 2023 from EVT801 Study
Oct 23, 2023
Change in substantial holding
Oct 16, 2023
Change of AGM date
Oct 13, 2023
Shareholder communication on the ASX de-listing process
Oct 11, 2023
Kazia announces intention to voluntarily de-list from ASX
Oct 11, 2023
Reinstatement to Official Quotation
Oct 10, 2023
Voluntary Suspension
Oct 6, 2023
Trading Halt
Oct 5, 2023
Presentations at upcoming scientific meetings
Sep 29, 2023
Acceptance of late-breaking abstract of PNOC022 data
rss_feed
RSS
Previous Page
arrow_back
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Page
10
…
Page
19
Next Page
arrow_forward
Select a page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19